Why is pT3 not a PORT indication for glottic larynx in the NCCN guidelines?  

NCCN list T3 as an indication for PORT for all head/neck subsites including supraglottic larynx with the sole exception of glottic larynx. (Some other sources include pT3 as indication)

Understanding that staging and LN involvement risk are different for pT3 larynx vs. other sites, and larynx preservation is preferred for T3 disease, what is the specific data/rationale for pT3 glottic larynx not needing adjuvant RT after surgery?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice